Mankind Pharma PAT grew by 29% in Q2FY25

New Delhi: Mankind Pharma India’s fourth 1 largest pharmaceutical Company today announced its financial results for the second quarter and six months ended 30 th September 2024. The information mentioned in this release is based on consolidated financial statements.

Q2 FY25 Performance Summary

•  Revenue from Operations at INR 3,077 Cr, up by 14% YoY o Domestic revenue at INR 2,796 Cr, up 11% YoY; Exports at INR 281 Cr, up 57% YoY

•  Reported EBITDA margin of 27.7% and PAT margin of 21.4%
•  Diluted EPS 1 of INR 16.3, up by 30% YoY (FV Re.1) H1 FY25 Performance Summary
•  Revenue from Operations at INR 5,970 crore, up by 13% YoY o Domestic revenue at INR 5,430 crore, up 10% YoY; Export at INR 540 crore, up 59% YoY
•  Reported EBITDA margin at 25.8%, up by 14% YoY with Adj. EBITDA 2 margin of 26.5% and PAT margin of 20.1% ? Diluted EPS 1 of INR 29.7, up by 20% YoY (FV Re.1) Domestic Business
•  Secondary 3 sales growth of 8.6% vs 8.0% IPM growth (1.1x to IPM) supported by o Strong outperformance of 3.4x volume growth to IPM o Strong outperformance of 1.3x in   chronic growth vs IPM chronic and 1.6x vs IPM
•  Growth partially impacted by o Regulatory headwinds in certain key products in acute segment o Certain initiatives adopted towards field force optimization to further enhance         efficiency
•  Ranked 2nd by volume with a market share of 5.9% in Q2FY25 vs 5.8% in Q2FY24
•  Consistently maintained #1 rank over last 7 years with prescription share of 15.4% in Q2FY25
•  Prescriber Penetration increased to 83.5% in Q2FY25

Read Also : JN Port Authority records around 12% rise in container traffic in October

Consumer Healthcare Business

•  Strong revenue growth of 20% YoY 4 in Q2FY25 propelled by steady growth in key brands like Manforce, Gas-o-fast, and HealthOk further aided by faster growth in Modern Trade, E-commerce and Q-Commerce channels
•  Strong growth in secondary sales2 for Manforce, Gas-o-fast and HealthOk of 15%, 28% and 27% YoY respectively
•  Gaining strong traction in recent strategic launches: Manforce ThinX and Epic (Premium category), Nimulid (Pain Management) etc.
•  With a focus on consistently increasing accessibility, Nimulid is now available in ~1,00,000 stores, Manforce Epic available in 25,000+ select stores, and Ovanews is available in 15,000 A+ stores.

Read Also : Hindustan Zinc shares plunges by 7% as government set to sell up to 10.56 crore shares

Exports

• Revenue growth of 57% YoY driven by increase in our base business supported by new launches in last 12-24 months.
•  During the quarter, we have launched 1 new product in US taking the total launched products to 42.  

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead.

In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 28 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 600 scientists.

Read Also : Indian Coast Guard DD General lays foundation stone for Tier-III Data Centre of Project DCG